Molitoris Bruce A
Crit Care. 2013 Sep 4;17(5):181. doi: 10.1186/cc12876.
Acute kidney injury (AKI), due to its increasing incidence, associated morbidity and mortality, and potential for development of chronic kidney disease with acceleration to end-stage renal disease, has become of major interest to nephrologists and critical care physicians. The development of biomarkers to diagnose AKI, quantify risk and predict prognosis is receiving considerable attention. Yet techniques to accurately assess functional changes within patients still rely on the use of an insensitive marker (creatinine), creatinine-based estimating equations and unreliable urinary tests. Therefore, it is critical that functional tests be developed and used in combination with biomarkers, thus allowing improved care in AKI and chronic kidney disease patient populations.
急性肾损伤(AKI)因其发病率不断上升、相关的发病率和死亡率,以及发展为慢性肾脏病并加速至终末期肾病的可能性,已成为肾脏病学家和重症监护医生主要关注的问题。用于诊断AKI、量化风险和预测预后的生物标志物的开发正受到广泛关注。然而,准确评估患者体内功能变化的技术仍依赖于使用不敏感的标志物(肌酐)、基于肌酐的估算方程和不可靠的尿液检测。因此,开发功能测试并将其与生物标志物结合使用至关重要,这样可以改善对AKI和慢性肾脏病患者群体的护理。